MD Biosciences announced the addition of its suite of in vivo and in vitro cancer models to its family of preclinical contract research services.
MD Biosciences’ oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression.
The comprehensive services include both syngeneic and xenograft models with readouts for longitudinal tumor monitoring (for some models), longitudinal blood phenotyping (immune cell distribution, biomarkers, etc.), end time-point primary/metastatic tumor evaluation, tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune etc.), biomarker analysis (blood, tumor tissue, spleen, lymph node etc.) and histological grading and evaluation of tumor specific tissue (H&E, IHC, etc.).
"Our onco-immunology research team is comprised of skilled scientists with deep-rooted expertise in a highly complex field," said Eddie Moradian, MD Biosciences CEO.
"We at MD Biosciences are excited to bring our high level of expertise and our novel models to assist sponsors and partners in reaching their programs’ developmental goals. This new suite of capabilities compliments our existing, best-in-class services in other disease areas."
MD Biosciences Preclinical Research Services is a leading provider of contract research in the core areas of inflammation, immunological, oncological, neurological and metabolic diseases. The suite of services includes a wide range of cell-based assays, in vivo disease models, translational models as well as models for the identification of the mode of action of novel drugs and compounds.